北京三诺佳邑生物技术

Beijing Sannuo Jiayi Biotechnology is a clinical-stage Chinese biotechnology company specializing in the development of adeno-associated virus (AAV) mediated gene therapies. The company focuses on addressing unmet medical needs in rare genetic diseases, particularly hematological and metabolic disorders. Its lead program, SNJ-101, is an investigational gene therapy for Hemophilia B currently undergoing clinical evaluation. By utilizing advanced vector engineering and manufacturing processes, Sannuo Jiayi aims to deliver durable therapeutic benefits through single-dose genetic interventions. The firm is headquartered in Beijing and has secured significant backing from leading venture capital firms.